#Crizotinib is used to treat certain types of non-small cell lung cancer (NSCLC) that has spread to nearby tissues or to other parts of the body.
#anticancer #cancertreatment
#oncology #oncology research
#cancermedicine #Bangladesh
Wechat 1: drug -international

$IOVA Have they ruled out accelerated approval in NSCLC?

#Mobocertinib is used to treat a certain type of non-small cell lung cancer (NSCLC).
#莫博替尼 #Mobonib #Mobocertinib
#Cancerdrug #Cancertreatment
#Oncology #Bangladesh

Contact Us For Order
Wechat 1: drug -international
Wechat 2: lifesaving-medicine

【PACIFIC2に続く2つめのnegative試験】

📚CheckMate73L試験（P3）

☑︎切除不能III期NSCLCに対する
❶ニボルマブ＋CRT併用
→ニボルマブ＋イピリムマブ地固め療法
は
❷従来のPACIFICレジメン
（CRT→デュルバルマブ地固め療法）
と比較してPFSの改善なし

news.bms.com/news/corporate…

Updated swimmer plot data from $MAIA showing a continuation of the positive survival data in both 2nd and 3rd line NSCLC.

Data cutoff is from late March (vs. early Jan previously).

Overall survival (OS) for third-line patients was 8.4 months at the data cut, which already…

As #ASCO24 approaches, this is a good review of the Key Opinion Leader sentiments toward the #ADAURA #ASCO23 plenary in NSCLC. KOL criticism of 'cheerleaders' while others discuss ethics of the control arm treatment...KOLs on the positive side discuss new standards of care and…

HOPE & Lung Cancer tattoos from the LUNGevity Foundation #HopeSummit24 were given to my grandchildren today as they spent time with me for 'Mother's Day.' I've been living 10 years with Stage IV NSCLC since Avii was born. He'll be 10 this year. Thank you, Tina Powell for your words. 😘

The OncoAlert🚨NEWSLETTER OUT
Covering May 2-8, 2024

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

✅ The Lancet Commission on #ProstateCancer
✅DESTINY-PanTumor01
✅Osimertinib+Local tx for brain🧠mets in EGFRm #NSCLC 🫁
✅ASCENT in Triple Negative…

#MET阻害薬 に獲得耐性を示した #MET遺伝子変異 陽性進行非小細胞 #肺がん に対する #カボザンチニブ の効果を検討する医師主導の第2相試験が2024年度中に始まることが明らかになりました。
medical.nikkeibp.co.jp/leaf/all/cance…

#吉非替尼 #Gefitinib
#Getinib 它用于治疗具有某些类型的异常表皮生长因子（ #EGFR ）基因且过去未接受过癌症药物治疗的转移性非小细胞肺癌（ #NSCLC ）患者。

Thank you Grey's Anatomy for highlighting our COSINR trial at UChicagoCancerCenter University of Chicago Radiation Oncology for cytoreductive ablative radiotherapy and immunotherapy for first-line metastatic NSCLC.

Great overview of resistance mechanisms to #KRAS inhibitors in #NSCLC at #RomeLung24 by AmbrogioLab. Different therapeutic vulnerabilities depending on whether resistance is intrinsic, acquired, or adaptive.

6- gingerol activate or induced p53( anti tumor protein) expression and arrest of cell cycle in NSCLC cells.
It also inhibited proliferation of cancer cells via ROS generation & DDR induction
J P Fanton DrRPalmquist
mdpi.com/2073-4409/12/2….

Honored to present at #ESTRO24 early results of QoL of ESTRO&EORTC Oligocare Cohort:
1033 patients treated w/SBRT and baseline QoL assessment :
- PS>0 : poorer QoL @ baseline
-BC,CRCP and NSCLC :poorer baseline QoL compared to prostate cancer
-@ 6 mos after SBRT no change in QoL

Fenglan Li et al. discover that quantitative parameters of dual-layer spectral computed tomography (DLCT) can help predict epidermal growth factor receptor (EGFR) mutation status in non-small cell #LungCancer (NSCLC) patients.

#InsightsIntoImaging

🔗 buff.ly/4a4npas

Triumph Over NSCLC: My Journey to Remission & Discovering FenBen youtu.be/DiCzCv1MCq8?si… via YouTube

#RomeLung24

Great talk by Fabrice Barlesi on how to advance stage III unresectable nsclc:

- non-oncogene+: additional IO (eg COAST trial)
- oncogene+: novel designs (eg kras, Durva➡️sotorasib in ctDNA+ only), & rarer groups (ALK, ⁦ETOP IBCSG Partners Foundation⁩ BOUNCE)

⁦OncoAlert⁩ #LCsM

Great presentation from Dr. Wu on ALINA - Brendon Stiles
AATS
oncodaily.com/59647.html

#AATS #Cancer #OncoDaily #Oncology #AATS 2024 #NSCLC

Dr. Rolf Stahel at #RomeLung24 presents long term survival data with immunotherapy in NSCLC. 5y survival are wonderful to see but lots of room for improvement. About 30% in PDL1 high but only 1% for PDL1 negative.

$CTMX $JANX plots side by side. Obvious that some cancers like CRC are harder but tumor shrinkage seen in esophageal and NSCLC where higher doses could see some responses. PDAC obviously the most promising.